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Background: Extracorporeal membrane oxygenation (ECMO) is a life-saving bridging procedure in patients with severe
acute respiratory distress syndrome (ARDS). Official indications for ECMO are unclear for immunocompromised and
HIV-positive patients affected by severe hypoxemia. Uncertainties are related to prognosis and efficacy of treatment
of the underlying disease. However, the care of patients with HIV infection has advanced since the introduction of
highly active antiretroviral therapy (HAART), with increased life expectancy and decreased mortality.
Case presentation: Three HIV-infected patients with AIDS were admitted to ICU and were treated with ECMO: a
21 years old Caucasian female with congenital HIV infection presented with Pneumocystis jirovecii pneumonia (PJP); a
38 years old Caucasian female with HIV-HCV infection and L. pneumophila pneumonia; a 24 years old Caucasian male
with fever, cough weight loss and PJP pneumonia. Two patients were alive, with a good immunovirological profile and
they went back to their previous quality of life. The last patient died with septic shock after three months of ICU stay.
Conclusion: ECMO was effective in three HIV-positive patients with an otherwise fatal respiratory failure. All patients
had severe immunosuppression and/or limited antiretroviral options. A multidisciplinary critical team is needed to
individualize the use of ECMO in immunocompromised patients, including those with HIV infection.
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Extracorporeal membrane oxygenation (ECMO) is a
feasible life-saving support therapy for patients with se-
vere acute respiratory distress syndrome (ARDS) that is
refractory to conventional mechanical ventilation (MV)
[1,2]. Key factors for the indication of ECMO are repre-
sented by prognosis of the underlying disease, timing,
quality of life of survivors and the possibility of being
lung transplant candidate [2].
Occurrence of ARDS in immunocompromised HIV-
positive in HIV-positive patients is associated to an ex-
tremely high mortality especially before the introduc-
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unless otherwise stated.[3]. Under these circumstances, ECMO is usually not
recommended in immunocompromised HIV-positive
patients that develop ARDS [2,3]. However, nowadays,
HIV-positive patients have variable levels of immune
function (T-CD4+ lymphocytes/microL) or viral suppres-
sion (levels of plasma HIV-RNA) and ARDS may be due
to opportunistic infections in antiretroviral-naïve patients
or to a bacterial pneumonia during HAART, with consid-
erable differences on the definition of immunocomprom-
ised status [3].
We report three cases of successful ECMO support in
patients with HIV infection and pneumonia by Pneumo-
cystis jirovecii (two cases) and Legionella pneumophila.Cases presentation
The first patient (female, 21 years old, BMI 15.6 Kg/m2,
PBW 52.4 kg) had a congenital HIV infection and pre-
sented with Pneumocystis jirovecii pneumonia (PJP) afterl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Main clinical characteristics of patients
Patient 1 Patient 2 Patient 3
Perinatally acquired HIV infection Previous IDU with HIV-HCV infection Newly diagnosed HIV infection
Diagnosis at admission PJP pneumonia after HAART
discontinuation
Legionella pneumophila pneumonia PJP pneumonia
HAART On HAART for 21 years, multiple
changes; low compliance
Compliant, multiple changes NA
Last HAART Darunavir/ritonavir, etravirine,
enfuvirtide and raltegravir:
spontaneously stopped in 2010.
Tenofovir, lamivudine, darunavir/
ritonavir
Started on 18 August: Emtricitabine/
tenofovir, darunavir/ritonavir, raltegravir,
maraviroc
HIV-RNA & CD4/mm3 at
admission
(HIV-RNA 386 cp/ml; T-CD4+
196 cells/mm3), HIV-RNA:
118.330 cp/ml; CD4: 2/mm3
(HIV-RNA suppressed; T-CD4+
200 cells/mm3), HIV-RNA: 500 cp/ml;
CD4: 170/mm3
HIV-RNA: 50728 cp/ml; CD4: 3/mm3
ICU length of stay (days) 35 22 81
ECMO duration (days) 20 13 24
Antibiotic and antifungal
treatment during ECMO
Cotrimoxazole 5 mg/kg q8h*;
fluconazole 200 mg; meropenem
1gr q8h.
Cotrimoxazole 5 mg/kg q8h*;
levofloxacin 500 mg q12h; rifampin
600 mg/die; pip/tazobactam 4,5 gr
q6h; fluconazole 400 mg/die.
Cotrimoxazole 5 mg/kg q8h*;
vancomycin 1gr q24h;metronidazole
250 mg q8h.
On day 2 after ECMO changed to:
vancomycin 750 gr bid, levofloxacin
750 mg/die, piperacillin/tazobactam
4,5 mg q6h, caspofungin 50 mg/die
(with loading dose of 70 mg/die),
clindamycin 600 mg q6h and
primaquine per os ganciclovir 250 mg
bid, due to concern for reduced plasma
concentrations of cotrimoxazole
On day 10 after ECMO changed to:
clindamycin 600 mg q6h; caspofungin
50 mg/die (with loading dose of
70 mg/die); primaquine per os; colistin
9 MU followed by 4.5 MU bid;
meropenem 2gr tid; liposomal
amphotericin B 150 mg; atovaquone
750 mg q6h
After cotrimoxazole switch to
clyndamicin, primaquine and
caspofungin there was a slow
improvement of respiratory function
and ECMO was removed.
After cotrimoxazole switch to
clyndamicin, primaquine and
caspofungin there was an
improvement of general conditions
and ECMO was removed.
HAART Restarted with tenofovir/emtricitabine,
raltegravir, darunavir / ritonavir,
enfuvirtide and maraviroc
As above As above
cp= copies; * dose based on trimethoprim component.
De Rosa et al. BMC Anesthesiology 2014, 14:37 Page 2 of 5
http://www.biomedcentral.com/1471-2253/14/37a 2-year HAART discontinuation (Table 1). This patient
was admitted to the emergency ward with fever, cough,
dyspnea and weight loss. Chest CT scan showed diffuse
and bilateral ground glass opacities. P. jirovecii (PJP) was
identified by immunofluorescence (IF), performed on
bronchoalveolar lavage (BAL) and other virus, bacterial
and fungal infections were excluded with appropriate
microscopic, cultural or molecular methods on BAL.
Galactomannan test was performed on BAL and blood
samples. Two days after the beginning of treatment with
steroids and cotrimoxazole, the patient developed mild
ARDS [4] that was initially treated with non-invasive
mechanical ventilation (NIV) in the Intensive Care Unit
(ICU). Later, ARDS evolved to the severe stage [4] and a
significant pneumo-mediastinum with subcutaneous em-
physema occurred. For this reason, eight days after the
onset of respiratory failure, the patient was referred to
the regional ECMO center.
Upon arrival at the referral ICU, the patient was intu-
bated, tension pneumothorax was treated and veno-venousECMO was initiated (19 and 20 F cannulas were inserted
into left and right femoral veins, respectively). The by-
pass was established with a blood flow of 3 L/min, corre-
sponding to 60% of cardiac output and sweep gas of
5.5 L/min. This setting allowed a super-protective ventila-
tory strategy that consisted in a tidal volume of 5 ml/kg
and a respiratory rate of 5 breaths/min (Table 2). This
strategy offered the advantage to rest the lung minimizing
the risk of ventilator-induced lung injury [5]. At the third
day of ECMO, the patient was successfully extubated and
ventilated with non-invasive ventilation (NIV) by face-
mask. Details of HAART, antibiotic and antifungal treat-
ments are shown in Table 1. After 20 days, ECMO was
stopped when arterial blood gases were satisfactory for at
least eight hours with a blood flow of 1.5 L/min and a
sweep gas of 0.5 L/min (Table 3). After 10 days, the pa-
tient was discharged to a step down ICU and then at
home. After 1 year of follow-up the plasma HIV-RNA
was negative (<20 copies/ml) and the T-CD4+ cell count
was 90 cells/microL.
Table 2 Ventilator settings before and after institution of ECMO
Before ECMO
VT (ml/kg PBW) or PIP (cmH2O) or SB RR (breaths/min) Pplat (cmH2O) PEEP (cmH2O) PaO2/FiO2
Patient 1 VT 6 35 28 10 120
Patient 2 VT 6 30 29 16 90
Patient 3 VT 6 25 28 16 100
During ECMO
Patient 1
Day1 PIP 20 5 NA 10 150
Day 3 PSV / NIV 5 26 NA 8 200
Day 7 SB 28 NA NA 180
Patient 2
Day1 VT 5 5 27 16 120
Day 3 VT 5 5 27 16 140
Day 7 PSV 10 22 NA 10 160
Patient 3
Day1 VT 5 5 26 16 100
Day 3 VT 5 5 26 16 90
Day 7 VT 5 5 26 16 90
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20.3 Kg/m2, PBW 52 Kg) that had a HIV-HCV infection
treated with different HAART regimens, achieving viro-
logical suppression (negative plasma HIV-RNA) with
T-CD4+ lymphocytes count of 200 cells/microL. After
five days of flu-like respiratory symptoms and fever, the
patient developed severe respiratory distress and was ad-
mitted to a peripheral hospital. Severe ARDS due to
pneumonia caused by L. pneumophila (urinary antigens)
was diagnosed. After two days, the patient was central-
ized to the ECMO center since refractory to conventional
protective MV.Table 3 Respiratory and ventilator variables before
stopping ECMO
Patient 1 Patient 2 Patient 3
Main variables
FiO2 0.4 0.4 0.4
PIP (cmH2O) SB 10 20
PEEP (cmH2O) SB 8 8
PaO2/FiO2 360 250 145
PaCO2 (mmHg) 38 42 44
RR (breaths/min) 22 21 26
Additional variables
CRS NA 33 13
Values were obtained after 6–8 hours of sweep gas 0.5 L/min and blood flow
1.5 L/min with gas flow oxygen concentration 0.21.
List of Abbreviations: VT (tidal volume), PIP (Peak inspiratory Pressure), SB
(spontaneous breathing), RR (respiratory rate), Pplat (plateau pressure), PEEP
(positive end expiratory pressure), PaO2/FiO2 (arterial pressure/inspired fraction
of oxygen), CRS (Compliance of respiratory system).A veno-venous ECMO (21 and 22 F cannulas were
inserted into left and right femoral veins, respectively)
was established, with a blood flow of 4 L/min (equal to
70% of cardiac output) and sweep gas of 7 L/min with
FiO2 of 100% (Table 2). After six days of treatment,
compliance of respiratory system (28 ml/cmH2O) im-
proved as a consequence of resolution of ARDS. Accord-
ingly, the patient was shifted to assisted breathing and
seven days later the patient was disconnected from the
by-pass when arterial blood gases were satisfactory for at
least eight hours with a blood flow of 1.5 L/min and a
sweep gas of 0.5 L/min, and the compliance of the re-
spiratory system was 33 ml/cmH2O) (Table 3). Details on
HAARTand antibiotic treatment are given in Table 1.
Eight days after centralization to the ECMO center,
the patient developed signs of liver toxicity with jaundice
(total bilirubin 28 mg/dl), ascites and elevated liver en-
zymes (AST/ALT 185/50 UI/mL) requiring interruption
of HAART; only levofloxacin monotherapy was contin-
ued. On day 22 the patient was transferred to the med-
ical ward and after 6 months of follow-up, she was alive
with a good immunovirological profile.
The third patient was a 24 years old male (BMI 23.5
Kg/m2, PBW 61 Kg) that was admitted to a peripheral
hospital with fever, cough and weight loss (30 kg in the
last three months). Chest CT scan showed diffuse and
bilateral ground glass opacities and BAL was positive
for P. jirovecii (PJP). Diagnosis of HIV infection was
made and there were no plasma CD4+ lymphocytes
detectable. Four days after the beginning of treatment
with steroids and cotrimoxazole for PJP, the patient
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invasive mechanical ventilation. Ten days after admis-
sion, the patient developed severe ARDS and he was cen-
tralized to the regional ECMO center. A veno-venous
ECMO (21 and 22 F cannulas were inserted into left and
right femoral veins, respectively) was established, with a
blood flow of 3.5 L/min and sweep gas of 6 L/min with
FiO2 of 100% (see Table 2). On the second day of ECMO,
HAART was started and was associated with virological
response but without immune recovery (after 1 month
on HAART: HIV-RNA 600 cp/ml; 3 CD4+ lymphocytes/
microL). During the ICU stay, he also had a bloodstream
infections by K. pneumoniae carbapenemase producing
(KPC-Kp). Details on HAART and antibiotic treatment
are given in Table 1. Full ECMO support remained un-
changed for three weeks and it was discontinued only
after 24 days when arterial blood gases were satisfactory
for at least eight hours with a blood flow of 1.5 L/min
and a sweep gas of 0.5 L/min (Table 3). However, the de-
velopment of lung fibrosis, typically associated with the
late phase of ARDS [6] left a severely impaired compli-
ance of the respiratory system. On day 81 the patient was
transferred to the ICU where he was initially admitted.
After three months by the initial ICU admission the pa-
tient died for septic shock.
Conclusion
To the best of our knowledge, this is the first report on
successful extracorporeal life support in patients with
HIV infection. There are clinical and ethical consider-
ations about ECMO support in patients with HIV infec-
tion and AIDS.
Evidence supporting ECMO as life saving treatment
for adults with respiratory failure are growing [1,2,7]
However, ECMO is a costly intervention that may carry
the risk of futility and serious side effects such as major
bleeding and infection. Under these circumstances, indi-
cation and selection criteria need to be better defined,
especially for the immune-compromised patients. In our
reports, ECMO was used in severe, life threatening re-
spiratory failure with etiological diagnosis and know-
ledge of the full potential of HAART, especially in the
first patient who had discontinued treatment in the pre-
vious two years.
Extracorporeal Life Support Organization (ELSO) guide-
lines suggest ECMO when the risk for mortality is at least
50% (as identified by PaO2/FiO2 < 150 and or Murray score
of 2–3) [8]. For immunocompromised patients, the guide-
lines do not propose absolute contraindications but suggest
to consider the individual risks/benefits balance. Only
leukopenia with absolute neutrophil count <500/mm3
and recent or expanding central nervous system hemor-
rhages are considered relative contraindications. In pa-
tients with HIV infection, ECMO may erroneously beconsidered futile because of the patient’s prognosis and
of the uncertainties regarding the efficacy of HAART.
Our reports show that ECMO is not futile when clini-
cians consider the immune-virological parameters with
the full potential of HAART success.
In the first patient there were critical considerations,
mainly represented by the concern for barotrauma after
failure of NIV; there were HIV-related considerations
such as the long history of HIV infection and HAART
along with extensive multiclass drug resistance. How-
ever, in the last years the availability of new drugs and
new classes of anti-retroviral allowed to achieve a high
probability of virological success even in patients harbor-
ing multi-resistant virus [9]. Moreover, the individual
level of compliance has been showed to be highly vari-
able over a long history of HAART [10]. In our case, al-
though a complex 6-drug based HAART was started, an
adequate counseling after the discharge from ICU along
with rapid clinical improvement reinforced patient’s ad-
herence, with treatment efficacy at 48-week.
L. pneumophila is the second most common cause of
ICU admission amongst severe community acquired
pneumonia (CAP) and PJP pneumonia is a frequent clin-
ical presentation in antiretroviral-naïve patients [11].
Under these circumstances, the issue of ECMO in the
last two patients may be more frequently encountered in
daily practice. In particular, our second patient, in whom
the ongoing HAART resulted in stable immunovirologi-
cal parameters, may perhaps suggest the inclusion of
ECMO into a treatment algorithm for HIV-positive pa-
tients undergoing HAART.
Special considerations are needed for the third patients
where the futility of ECMO support was confuted by the
excellent virological response to HAART, even if the ab-
sence of immune function recovery in the short term
may not be easily predicted.
Predefined criteria to wean patients from ECMO are
still lacking. In our center, satisfactory blood gases, ob-
tained with sweep gas 0.5 L/min and blood flow of
1.5 L/min (gas flow oxygen concentration 0.21) for 6–8
hours, is the main criteria. Moreover, the improvement
of respiratory system compliance (Crs >30) is an add-
itional criteria that we consider. In particular, we did not
report the value of compliance of the first patient be-
cause she was breathing spontaneously when ECMO
was stopped.
In conclusion, ECMO was effective in three HIV-
positive patients with an otherwise fatal respiratory fail-
ure, even with severe immunosuppression or limited
antiretroviral options. Two patients went back to their
previous quality of life. Unfortunately, the third patient
needed a prolonged ICU stay and did not have any re-
covery of immune function and died after three months
by the hospital admission. This case series suggest that a
De Rosa et al. BMC Anesthesiology 2014, 14:37 Page 5 of 5
http://www.biomedcentral.com/1471-2253/14/37multidisciplinary team, involving critical care and infec-
tious diseases experts, is mandatory to define whether
ECMO is an adequate therapeutic option also in im-
munocompromised patients, including those with HIV
infection and AIDS.
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